All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The mortality from cryptococcal meningitis remains high at 6 months, about 50% in several studies despite the availability of antiretroviral therapy (ART) and improved fungal regimens. Most of the mortality occurs early during the antifungal initiation and consolidation phase.\[[@pone.0209337.ref001], [@pone.0209337.ref002]\] Cryptococcal infection occurs by inhalation through the respiratory system where the fungal organisms multiply in the lungs, leading to infection.\[[@pone.0209337.ref003]\] *Cryptococcus* then escapes from the lung into the bloodstream where the yeast persists before invading the brain.\[[@pone.0209337.ref004]\]

Neutrophils have been shown to be efficient in killing several strains of *C*. *neoformans* in vitro.\[[@pone.0209337.ref005]\] Neutrophil recruitment into the lungs is observed during the early phase of cryptococcal infection.\[[@pone.0209337.ref006]\] *Cryptococcus* has demonstrated chemotactic activity on the neutrophils in vitro,\[[@pone.0209337.ref007]\] though paradoxically, the capsular polysaccharide glucuronoxylomannan (GXM) has been shown to inhibit neutrophil migration \[[@pone.0209337.ref008]\] and block neutrophil binding of fungal cells. \[[@pone.0209337.ref009]\]

The role of neutrophils in cryptococcal infection is still debated as either noncontributory or even detrimental because cryptococcosis is seen primarily in patients with dysfunctions in adaptive immunity and not in patients with neutropenia.\[[@pone.0209337.ref004]\] Animal studies have shown improved survival of mice transiently depleted of neutrophils at the time of pulmonary infection with *Cryptococcus* \[[@pone.0209337.ref010], [@pone.0209337.ref011]\] which appears to be caused by the absence of neutrophil-mediated inflammation.\[[@pone.0209337.ref012]\]

However, other mouse models have supported the protective role on neutrophils with an increased number of neutrophils associated with lesser fungal burden.\[[@pone.0209337.ref013], [@pone.0209337.ref014]\] In vivo imaging studies have demonstrated neutrophils directly removing *Cryptococcus* from the brain vasculature.\[[@pone.0209337.ref014], [@pone.0209337.ref015]\] Furthermore, the augmentation of neutrophil defenses by administration of granulocyte colony stimulating factor (G-CSF) to enhance anti-cryptococcal activity has been demonstrated in vitro \[[@pone.0209337.ref016]\], animal models\[[@pone.0209337.ref017]\], as well as in persons living with AIDS. \[[@pone.0209337.ref018], [@pone.0209337.ref019]\] A deficiency of myeloperoxidase, an enzyme with the most abundant expression in neutrophils, has been found to significantly shorten the survival of *Cryptococcus* infected mice with higher brain fungal burden. \[[@pone.0209337.ref020]\]

Neutrophil counts, either high or low, may have prognostic implications in Human immunodeficiency virus infection (HIV) patients with cryptococcal meningitis. Our objective was to examine the association between blood neutrophil counts and outcomes in terms of mortality, the incidence of bacterial infections including Mycobacterium tuberculosis and hospitalization among HIV-infected patients presenting with cryptococcal meningitis.

Materials and methods {#sec006}
=====================

Data from participants who were enrolled in either the Cryptococcal Optimal ART Timing (COAT) trial or the Adjunctive Sertraline for Treatment of Cryptococcal Meningitis (ASTRO-CM) trial (pilot and randomized phases) were used for this analysis. The COAT trial enrolled Ugandan and South African HIV-infected, ART-naive individuals diagnosed with a first episode of cryptococcal meningitis from 2010--2012, as previously described.\[[@pone.0209337.ref001]\] The ASTRO-CM pilot trial was an open-label dose-finding study of adjunctive sertraline conducted in Uganda from August 2013 to August 2014 followed by a randomized treatment trial from August 2014 through May 2017.\[[@pone.0209337.ref021]\] Both studies excluded pregnant women and patients \<18 years of age. The diagnosis of cryptococcal meningitis was by cerebrospinal fluid (CSF) cryptococcal antigen testing at Mulago National Referral Hospital, Kampala, Uganda (COAT and ASTRO-CM), Mbarara Hospital, Mbarara, Uganda (COAT and ASTRO-CM), or G.F. Jooste Hospital, Cape Town, South Africa (COAT). All participants in both trials received combination induction therapy with amphotericin B deoxycholate (0.7--1.0 mg/kg/day) and fluconazole 800 mg/day. In addition, we administered sertraline (100--400 mg/day) to all participants in the ASTRO-CM pilot trial. ASTRO trial participants were randomized to receive either sertraline (400 mg/day) or placebo during induction therapy. Blood samples were taken in EDTA bottle and analyzed within 12 hours after the venepuncture. A complete blood count was done on a Sysmex XS-1000*i* Automated Haematology Analyzer. However, thin blood films were not done. Neutrophil levels were obtained at the time of cryptococcal meningitis diagnosis in both trials. Follow-up neutrophil data was measured for COAT trial participants at 1, 2, 5, 9, 13, and 27 weeks from cryptococcal diagnosis.

We summarised the absolute neutrophil counts at cryptococcal meningitis diagnosis (all participants) and subsequent weeks (COAT participants only). Three groups were categorized by baseline neutrophil count (≤1000, 1001--3500, and \>3500 cells/mm^3^). Neutropenia was defined as absolute neutrophil count ≤1000 cells/mm^3^ in line with the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. The category formed by baseline neutrophil counts \> 3500 cells/mm^3^ was based on the upper quartile of the data from all participants. Baseline characteristics and outcomes within 30 days were presented and compared between the three groups with Chi-squared and Kruskal-Wallis tests as appropriate. Outcomes considered included 30-day mortality (including sepsis and TB-related mortality) and the incidence of infection and tuberculosis. The infections were documented if they fulfilled the DAIDs toxicity table grade 3 and above with investigations done at physicians' discretion. Participants with suspected sepsis according to the systemic inflammatory response syndrome (SIRS) criteria \[[@pone.0209337.ref022]\] had blood cultures in the COAT study. However, this was not possible in the ASTRO study because of budgetary limitations, and most of the diagnoses were based on clinical criteria. Tuberculosis was investigated by chest radiographs and abdominal ultrasound, sputum microscopy for acid-fast bacilli in the COAT trial and Xpert MTB/RIF (Cepheid, Sunnyvale, CA) in the ASTRO trial.\[[@pone.0209337.ref023], [@pone.0209337.ref024]\] We did not perform mycobacteria blood cultures.

To model the association between baseline neutrophil count and 30-day mortality, cohort-adjusted and fully-adjusted Cox proportional hazards models were examined with (a) neutrophil count on a continuous scale (per 1000 cells/mm^3^), and (b) comparing the three baseline neutrophil groups (comparing the lower and upper groups with the 1001--3500 cells/mm^3^ group). All models were adjusted for study cohort and are summarized with hazard ratios and 95% confidence intervals. The fully adjusted Cox models considered baseline prognostic variables known to be associated with cryptococcal-related deaths: Glasgow coma scale, sex, ART status, CSF opening pressure, and CSF quantitative culture.

Neutrophil counts were obtained during follow-up for the COAT study only. For COAT participants with follow-up blood neutrophil data available, unadjusted and fully adjusted Cox proportional hazards models considering time-dependent neutrophil count (per 1000 cells/mm^3^ increase) were used to examine the relationships between neutrophil count and 12-month mortality and rehospitalization.

All research participants or their surrogate provided written informed consent. Ethical approval occurred from the Uganda National Council of Science and Technology (UNCST), Mulago Hospital Research and Ethics Committee, Makerere University Institutional Review Board, University of Cape Town institutional Review Board and University of Minnesota.

Results {#sec007}
=======

Baseline characteristics {#sec008}
------------------------

The baseline characteristics of participants are described in [Table 1](#pone.0209337.t001){ref-type="table"}, overall and by baseline blood neutrophil category (≤1000, 1001--3500, or \> 3500 cells/mm^3^). Baseline neutrophil data was available for 801 participants: 238 (30%) who were eligible for COAT, and 563 (70%) who were eligible for ASTRO. The median (IQR) blood neutrophil count was 2100 (1400, 3300) cells/mm^3^. The median (IQR) age was 35 (30--40), with male sex accounting for 61% of the participants. The proportion with a Glasgow coma scale (GCS) \<15 (altered mental status) was 22%, 41% and 50% for the baseline neutrophil groups ≤ 1000, 1001--3500 and \> 3500 cells/mm^3^, respectively (p\<0.001). The median (IQR) CD4 count was 18 (7, 54) cells/mm^3^, and was significantly lower in the baseline neutrophil group ≤ 1000 cells/mm^3^ group (p = 0.02). At cryptococcal meningitis diagnosis, 34% of the participants were on antiretroviral therapy (all from the ASTRO study), and of those 16% were on a zidovudine (AZT)-containing regimen.

The median (IQR) CSF opening pressures were lower in the baseline neutrophil ≤ 1000 group (p = 0.02). Approximately 14% of participants were screened for study enrolment while already on amphotericin, with a median (IQR) of 2 (2--3) doses prior to study screening. C-reactive protein (CRP) was measured in the day 6--11 window for 162 (20%) of participants. For those with a CRP measurement, the medians were 42, 63 and 84 for the baseline neutrophil groups ≤ 1000, 1001--3500 and \> 3500 cells/mm^3^, respectively (p = 0.02).

10.1371/journal.pone.0209337.t001

###### Baseline demographics by neutrophil group.

![](pone.0209337.t001){#pone.0209337.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                     Neutrophils at Screening (cells/mm^3^)                                                                       
  ------------------------------------------------------------------ ---------------------------------------- --------------------- ---------------------- ---------------------- ---------
  No. People                                                         801                                      98                    520                    183                     

  Neutrophil count, median cells/mm^3^                               2100 \[1400, 3300\]                      750 \[590, 910\]      1960 \[1490, 2510\]    4870 \[4030, 6060\]     

  Age, median (IQR) years                                            35 \[30, 40\]                            35 \[30, 38\]         35 \[30, 42\]          35 \[29, 41\]          0.37

  Male gender, N (%)                                                 486 (60.7%)                              57 (58.2%)            318 (61.2%)            111 (60.7%)            0.86

  Glasgow Coma Scale (GCS) \< 15, N (%)                              326 (40.8%)                              22 (22.4%)            213 (41.0%)            91 (49.7%)             \<0.001

  TB prevalent at meningitis diagnosis                               58 (7.2%)                                9 (9.2%)              37 (7.1%)              12 (6.6%)              0.71

  Cohort                                                                                                                                                                          0.26

      COAT                                                           238 (29.7%)                              23 (23.5%)            155 (29.8%)            60 (32.8%)              

      ASTRO                                                          563 (70.3%)                              75 (76.5%)            365 (70.2%)            123 (67.2%)             

  HIV Metrics                                                                                                                                                                      

      CD4 cells/mm^3^                                                18 \[7, 54\]                             11 \[5, 37\]          18 \[7, 57\]           20 \[8, 51\]           0.02

      On antiretroviral therapy                                      275 (34.3%)                              41 (41.8%)            174 (33.5%)            60 (32.8%)             0.24

      On zidovudine (AZT) [^2^](#t001fn002){ref-type="table-fn"}     43 (15.6%)                               6 (14.6%)             31 (17.8%)             6 (10.0%)              0.35

  CSF Metrics                                                                                                                                                                      

      Opening pressure (OP), mmH~2~O                                 268 \[180, 400\]                         220 \[170, 345\]      270 \[180, 390\]       280 \[180, 480\]       \< .01

      OP \> 250 mmH~2~O                                              377 (53.9%)                              34 (39.5%)            244 (54.2%)            99 (60.7%)             \< .01

      Quantitative culture[^3^](#t001fn003){ref-type="table-fn"},\   4.9 \[3.8, 5.6\]                         4.9 \[3.7, 5.3\]      4.8 \[3.7, 5.6\]       4.9 \[4.2, 5.7\]       0.32
  log~10~Colony Forming Unit(CFU)/ml                                                                                                                                              

      Sterile culture                                                64 (8.3%)                                7 (7.4%)              41 (8.2%)              16 (9.1%)              0.88

      White blood cells \< 5, cells/mm^3^                            434 (57.5%)                              55 (60.4%)            275 (56.4%)            104 (59.1%)            0.68

  On Amphotericin at screening                                       110 (13.7%)                              14 (14.3%)            66 (12.7%)             30 (16.4%)             0.45

      Doses of amphotericin[^4^](#t001fn004){ref-type="table-fn"}    2 \[2, 3\]                               2 \[2, 3\]            2 \[2, 3\]             2 \[2, 3\]             0.45

  No. with CRP measured[^5^](#t001fn005){ref-type="table-fn"}        162                                      23                    100                    39                      

      CRP, mg/L                                                      63.3 \[42.3, 121.2\]                     42.4 \[27.2, 79.1\]   63.3 \[44.6, 119.9\]   84.0 \[47.1, 140.2\]   0.02
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Data are median with (P25, P75) or N (%). P-values from Kruskal Wallis or chi-square tests.

^2^Among those on ART.

^3^Not including sterile cultures.

^4^Among those on amphotericin at screening.

^5^Measured 6--11 days after cryptococcal meningitis diagnosis.

Associations between baseline neutrophils and 30-day outcomes {#sec009}
-------------------------------------------------------------

For those with baseline neutrophils ≤1000, 1001--3500, and \>3500 cells/mm^3^, respectively, 30-day mortality was 31%, 31%, and 51% (p\<0.001; [Table 2](#pone.0209337.t002){ref-type="table"}). The proportions of those deaths related to sepsis and TB were not significantly different between the baseline neutrophil groups. The incidence (within 30 days) of infections and TB also did not differ between the groups.

10.1371/journal.pone.0209337.t002

###### Thirty-day outcomes[^1^](#t002fn001){ref-type="table-fn"} by neutrophil group.

![](pone.0209337.t002){#pone.0209337.t002g}

                          Neutrophils at Screening (cells/mm^3^)                              
  ----------------------- ---------------------------------------- ------------- ------------ ---------
  **No. People**          98                                       520           183           
  30-Day Outcome                                                                               
  Death                   30 (30.6%)                               159 (30.6%)   94 (51.4%)   \<0.001
      Related to sepsis   3 (3.1%)                                 20 (3.8%)     11 (6.0%)    0.38
      Related to TB       1 (1.0%)                                 5 (1.0%)      4 (2.2%)     0.43
  Incident infection      5 (5.1%)                                 18 (3.5%)     5 (2.7%)     0.59
  Incident TB             1 (1.0%)                                 14 (2.7%)     1 (0.5%)     0.16

^1^Data are N (%) with the specified event within 30 days.

^2^P-values are from chi-square tests.

[Fig 1](#pone.0209337.g001){ref-type="fig"} presents a Kaplan-Meier curve for mortality within 30 days for the three-baseline neutrophil groups and shows that the survival probability is lowest for those with baseline neutrophils \> 3500 cells/mm^3^. [Table 3](#pone.0209337.t003){ref-type="table"} presents the results from model associations between neutrophil counts and outcomes. The cohort-adjusted hazard ratio per 1000 cells/mm^3^ increase in baseline blood absolute neutrophil count was 1.10 (95% CI: 1.06, 1.14; p\<0.001). Results were similar in a fully adjusted model. Compared to those with baseline blood neutrophils 1001--3500 cells/mm^3^, there was a significantly increased risk of 30-day mortality in those with baseline blood neutrophil count \>3500 cells/mm^3^ (cohort adjusted hazard ratio = 2.06, 95%CI, 1.60 to 2.66; p\<0.001), but no difference in risk for those with baseline blood neutrophil count ≤1000 cells/mm^3^ (hazard ratio = 1.00, 95%CI, 0.68 to 1.48; p\>0.99), with results again being similar with fully adjusted models.

![Kaplan-Meier curve describing the survival patients with cryptococcal meningitis by the absolute neutrophil count.\
The lines represent the absolute neutrophil levels \< = 1000 = black dotted, 1001--3500 = grey solid, \> 3500 = black solid.](pone.0209337.g001){#pone.0209337.g001}

10.1371/journal.pone.0209337.t003

###### Model associations between neutrophil counts and outcomes.

![](pone.0209337.t003){#pone.0209337.t003g}

                                                                                                                               Cohort Adjusted Model[^1^](#t003fn001){ref-type="table-fn"}   Multivariable Model[^2^](#t003fn002){ref-type="table-fn"}                       
  ---------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------- ------------------- ---------
  30-day mortality                                           Per 1000 count/mm^3^ increase in baseline neutrophils             1.10 (1.06, 1.14)                                             \<0.001                                                     1.09 (1.04, 1.13)   \<0.001
  30-day mortality                                           Compared to baseline neutrophil count of 1001--3500 cells/mm^3^                                                                                                                                                  
                                                             ≤ 1000 cells/mm^3^                                                1.00 (0.68, 1.48)                                             \>0.99                                                      1.01 (0.65, 1.57)   0.96
                                                             \> 3500 cells/mm^3^                                               2.06 (1.60, 2.66)                                             \<0.001                                                     1.85 (1.40, 2.44)   \<0.001
  12-month mortality[^3^](#t003fn003){ref-type="table-fn"}   Per 1000 count/mm^3^ increase in time-updated neutrophil counts   1.16 (1.07, 1.24)                                             \<0.001                                                     1.16 (1.09, 1.24)   \<0.001
  Re-hospitalization[^3^](#t003fn003){ref-type="table-fn"}   Per 1000 count/mm^3^ increase in time-updated neutrophil counts   0.98 (0.82, 1.17)                                             0.83                                                        0.87 (0.69, 1.09)   0.23

^1^30-day mortality outcomes are adjusted for the cohort (COAT or ASTRO). Outcomes associated with time-updated neutrophil counts are for COAT only and are unadjusted.

^2^Additionally adjusted for sex, Glasgow coma scale \< 15, baseline ART status, baseline opening pressure \> 250 mm H~2~O, and baseline quantitative culture.

^3^COAT participants only.

For the COAT participants with follow-up neutrophil counts measured, [Fig 2](#pone.0209337.g002){ref-type="fig"}, presents the neutrophil distribution at screening and weeks 1, 2, 5, 9, 13 and 27. By week 5, when the median neutrophil count decreased from screening, generally, all COAT participants were started on an efavirenz-containing antiretroviral therapy regimen, with 82% also on a zidovudine-containing regimen. Neutropenia (≤ 1000 cells/mm3) in the COAT study at screening and weeks 5, 9 and 13 was 11%, 30%, 44%, and 30%, respectively. While neutropenia increased over time for COAT participants, results in [Table 3](#pone.0209337.t003){ref-type="table"} from models with time-updated neutrophil counts (per 1000 cell/mm^3^ increase) show that increased neutrophil counts are associated with increased mortality (unadjusted hazard ratio = 1.16, 95% CI 1.07--1.24; p\< 0.001). There was no significant association with time-updated neutrophils and re-hospitalization.

![This represents the data from the COAT study reflecting the changing neutrophil count over time.\
The red horizontal lines represent neutrophil count cut points of 1000 cells/mm^3^ and 3500 cells/mm^3^ (as used in other tables), and the blue points and line represent the means over time.](pone.0209337.g002){#pone.0209337.g002}

Discussion {#sec010}
==========

This study demonstrated that higher blood neutrophil counts at the baseline in HIV-infected patients with cryptococcal meningitis is associated with increased mortality. This association between higher blood neutrophil count and mortality is maintained even during long-term follow up of these patients. The baseline neutropenia and early decline in blood neutrophil counts during the consolidation phase of antifungal treatment was not associated with increased mortality.

The average baseline neutrophil count was 2,100 cells/mm^3^, comparable to other healthy population-based reference values in other studies done on the African continent.\[[@pone.0209337.ref025]--[@pone.0209337.ref027]\] The median (range) neutrophil count in healthy volunteers in Malawi was 2,100 (700--4500) cells/mm^3^, thought to be lower than the standard reference values due to the common African-derived ''null" variant (rs2814778) of the Duffy antigen receptor for chemokines (DARC) gene.\[[@pone.0209337.ref028]\] The average neutrophil count in our study is comparable to that found in HIV-infected Nigerian population where the mean neutrophil count was 2,320 ±1,580 neutrophil/mm^3^.\[[@pone.0209337.ref029]\]

The prevalence of baseline absolute neutropenia, defined in this study as a neutrophil count \<1000/mm^3^, was 12%. This is more than the 7% among HIV-infected American women,\[[@pone.0209337.ref030]\] but comparable to what was found in a multi-continent study, where the frequencies of neutropenia (absolute neutrophil count \<1,300/mm^3^ at the initiation of antiretroviral therapy were 14%.\[[@pone.0209337.ref031]\] Neither baseline neutropenia nor neutropenia at any time was associated with mortality or hospitalization among cryptococcal patients at 30 days or 12 months of observation. Those with neutropenia had a lower proportion of patients with poor prognostic factors, such as the Glasgow coma scale \<15 (altered mental status) or high CSF opening pressures.\[[@pone.0209337.ref032]--[@pone.0209337.ref034]\] Levine et al also found no association between neutropenia and mortality in HIV-infected women in the US followed up for 7.5 years.\[[@pone.0209337.ref030]\] Neutropenic mice given a pulmonary *C*. *neoformans* infection survived significantly longer than control mice with mean normal neutrophil count.\[[@pone.0209337.ref010]\] Neutropenia may be protective in cryptococcal infection because it is associated with alteration of the immune response between Type 1 T helper (Th1) to Type 2 T helper (Th2) response especially in the early phase of the infection.\[[@pone.0209337.ref010], [@pone.0209337.ref035]--[@pone.0209337.ref038]\]

On the contrary, there was a 10% increase in the risk of death within 30 days for every 1000 cells/mm^3^increase in baseline neutrophil count. Patients with an increased baseline blood neutrophil count (\>3500 cells/mm^3^) were two-fold more likely to die than those with baseline neutrophil counts between 1001 and 3500 cells/mm^3^. This remained so even after adjusting for known poor prognostic factors in cryptococcal meningitis like low Glasgow coma scale, ART status, CSF opening pressure, and CSF quantitative cultures.\[[@pone.0209337.ref001], [@pone.0209337.ref033], [@pone.0209337.ref034]\] The pattern was maintained in the longitudinal follow up of patients where the relatively increased neutrophil count was associated with mortality. Leukocytosis, in general, is associated with cryptococcal mortality. Jarvis et al found that the patients with leukocytosis of \>10,000/mm^3^ had 8.7-fold higher odds of mortality. In that South African study, patients with neutrophil counts \<500/mm^3^ were excluded.\[[@pone.0209337.ref034]\] Another study from Taiwan among HIV-negative patients with cryptococcal meningitis also found that patients with leukocytosis \>10,000/mm^3^ had 4.3- fold higher odds of mortality even though this effect was lost in multivariate analysis.\[[@pone.0209337.ref039]\] Scriven et al described a similar pattern of mortality among sixty HIV positive patients with cryptococcal meningitis in South Africa with a higher circulating white blood cell counts among those who died compared with the survivors (median, 6500 cells/mm^3^; IQR, 3900--7400 cells/mm^3^ vs 4400 cells/mm^3^; IQR, 2800--5800 cells/mm^3^; P = .020). Most of this leukocyte difference was attributed to higher relative neutrophil counts with percentages of 76.8% (68.8--82.6) in those who died versus 67.5% (54.6--75.8) in those who survived. \[[@pone.0209337.ref040]\] Bisson et al published similar results in HIV-infected adults initiating ART with CD4 T-cell counts \<50 cells/mm^3^ who were followed up for 48 weeks. The median absolute neutrophil count was 1900/mm^3^ in those who died compared to 1600/ mm^3^ those who survived.\[[@pone.0209337.ref041]\] One possible explanation for higher neutrophil counts being associated with mortality is the possibility of co-infections. Rajasingham et al have previously reported a15% incidence of nosocomial drug-resistant bacteremia in patients in the COAT study.\[[@pone.0209337.ref042]\] Kerkhoff et al reported that among HIV-infected patients, having pulmonary tuberculosis was associated with an adjusted risk ratio of 2.6 (95%CI, 1.5--4.5) for having an absolute neutrophil count higher than the median value (p = 0.0006). In that cohort, the adjusted risk ratio was 6.8-fold higher for having tuberculosis when having neutrophilia defined as \> 7500 neutrophils/mm^3^.\[[@pone.0209337.ref043]\] Lowe et al have found that a neutrophilia was associated with a three-fold higher risk of mortality in a predominantly HIV-negative population with tuberculosis.\[[@pone.0209337.ref044]\] We assessed for tuberculosis in most of our study patients using a clinical case definition, chest X-rays and sputum according to the standard of care at the time and found no association. The other possible cause of mortality in HIV infected patients may be immune reconstitution inflammatory syndrome (IRIS). Elevated CRP levels, which are associated with paradoxical IRIS\[[@pone.0209337.ref045], [@pone.0209337.ref046]\], were significantly higher in the high absolute neutrophil group. Weisner et al. demonstrated that impaired CD4 Helper responses in immunosuppressed mice were responsible for switching between an eosinophilic and neutrophilic response to cryptococcal infection. A neutrophil response was associated with worse outcomes compared to eosinophil response in mice cryptococcal pulmonary infections.\[[@pone.0209337.ref047]\] Neutrophils activation as evidenced by high neutrophil CD64 levels has been found to play a role in systemic inflammation in HIV infected patients initiating ART\[[@pone.0209337.ref048]\] and may play a role in IRIS as they have been found to be activated in TB-IRIS. \[[@pone.0209337.ref049]\] Vlasova-St. Louis et al using genome wide transcriptomic analysis have found higher transcripts encoding markers for activated granulocytes, tissue infiltration and destruction among subjects that developed cryptococcal immune reconstitution syndrome.\[[@pone.0209337.ref050]\] Higher neutrophil percentages and neutrophil to lymphocyte ratios have also been found to be associated with mortality in patients with community acquired pneumonia and other chronic medical conditions.\[[@pone.0209337.ref051], [@pone.0209337.ref052]\] Curbelo et al hypothesize that the mortality is attributable to the sustained immune response rather than the infectious process.\[[@pone.0209337.ref051]\] Higher neutrophil count is associated with a Th1 response that is more robust and likely to cause more tissue damage.\[[@pone.0209337.ref010]\]

Prognostic markers are important in cryptococcal meningitis because cryptococcosis is highly prevalent and associated with high mortality, especially in sub-Saharan Africa.\[[@pone.0209337.ref053], [@pone.0209337.ref054]\] It is thought that these prognostic factors have regional variation \[[@pone.0209337.ref055]--[@pone.0209337.ref057]\]. A systematic review by Paquier et al has significantly highlighted these differences to include the economic status of the country, ART status, the induction therapies used, as well as the person's HIV-status. The major prognostic factors in HIV-cryptococcal meningitis patients for long-term mortality were altered neurological status, low CD4 cell count, high CSF fungal/Cryptococcal antigen burden, older age at diagnosis and possibly immune reconstitution.\[[@pone.0209337.ref058]\] Lower CD4 counts \<50 cells/mm^3^ in Uganda are associated with slightly higher mortality.\[[@pone.0209337.ref059]\] Despite the improvements in care, mortality is unchanged hence the need for new prognostic markers to identify those at risk and the causes of mortality.

While the higher neutrophil count is associated with mortality, the mechanism is not clear, and the pathophysiology is unknown. Higher neutrophils may be due to other undetected co-infections, but there was no statistical significance in the incidence of infections between the neutrophil groups in our study. Other conditions such as anemia and known mycobacterial infections which are known prognostic factors for death were adjusted for and not found to be significant \[[@pone.0209337.ref060]\]. A complete blood count is easily accessible and a routine test that is available even in many resource-limited settings. Getting a readily accessible test that may have implications for mortality in HIV-infected patients with cryptococcal meningitis is likely of value.

Conclusion {#sec011}
==========

Higher blood neutrophil counts in HIV-infected patients with cryptococcal meningitis were associated with mortality. Neutrophils role requires further investigation as to whether this a mediator directly contributing to mortality or merely a marker of underlying pathologies that increase mortality risk. Absolute neutropenia was not associated with mortality.
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